Ion Beam Applications SA (0GZK.L)

16,98 +0,38 (+2,29%) Alla chiusura: 05:50PM BST

Ion Beam Applications SA

3, Chemin du Cyclotron
Louvain-la-Neuve 1348
Belgium
32 1 047 58 11
https://www.iba-worldwide.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 1.986

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Pierre Mottet	Chairman of The Board	52,5k	N/D	1962
Mr. Olivier Legrain	CEO, MD & Executive Director	880k	N/D	1968
Mr. Yves Jongen	Founder, Chief Research Officer, MD & Executive Director	576,92k	N/D	1947
Ms. Soumya Chandramouli	Chief Financial Officer	N/D	N/D	1977
Mr. Frederic Nolf	Chief Human Resources & Sustainability Officer	N/D	N/D	1972
Marc Van der Burght	Chief Operation Officer	N/D	N/D	N/D
Olivier Lechien	Corporate Communication Director	N/D	N/D	N/D
Thomas Canon	Sustainability Program Director	N/D	N/D	N/D
Bruno Scutnaire	President of IBA RadioPharma Solutions	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

Governance aziendale

L'ISS Governance QualityScore di Ion Beam Applications SA al 1 maggio 2024 è 9. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 9; diritti degli azionisti: 9; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.